125

Mesalazine 500mg Slow Release Tablets (Active Ingredient Released from Duodenum to Rectum)

Prescriber Criteria: Consultant Gastroenterologist
Consultant Paediatrician
Consultant Surgeon

Outpatient and Inpatient Use:

1. Inflammatory Bowel Disease

To be used in patients who require a time-dependent release of mesalazine.

Duration of Approval:
2 years